Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;238(8):1651-1669.
doi: 10.1002/jcp.31048. Epub 2023 Jun 3.

Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

Faizah Farooq  1 , Asif Amin  1 , Umer Majeed Wani  1 , Asif Lone  2 , Raies A Qadri  1
Affiliations
Review

Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

Faizah Farooq et al. J Cell Physiol. 2023 Aug.

Abstract

Resistance to chemotherapy and targeted therapies constitute a common hallmark of most cancers and represent a dominant factor fostering tumor relapse and metastasis. Fibronectin, an abundant extracellular matrix glycoprotein, has long been proposed to play an important role in the pathobiology of cancer. Recent research has unraveled the role of Fibronectin in the onset of chemoresistance against a variety of antineoplastic drugs including DNA-damaging agents, hormone receptor antagonists, tyrosine kinase inhibitors, microtubule destabilizing agents, etc. The current review summarizes the role played by Fibronectin in mediating drug resistance against diverse anticancer drugs. We have also discussed how the aberrant expression of Fibronectin drives the oncogenic signaling pathways ultimately leading to drug resistance through the inhibition of apoptosis, promotion of cancer cell growth and proliferation.

Keywords: DNA damaging drugs; apoptosis; chemoresistance; extracellular matrix; fibronectin; tumor microenvironment.

PubMed Disclaimer

References

REFERENCES

    1. Albrecht, M., Renneberg, H., Wennemuth, G., Möschler, O., Janssen, M., Aumüller, G., & Konrad, L. (1999). Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance. Histochemistry and Cell Biology, 112, 51-61.
    1. Ali, S., Rasool, M., Chaoudhry, H., Pushparaj, P. N., Jha, P., Hafiz, A., Mahfooz, M., Sami, G. A., Kamal, M. A., Bashir, S., Ali, A., & Jamal, M. S. (2016). Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation, 12(3), 135-139.
    1. Alkhatib, M. H., Al-Otaibi, W. A., & Wali, A. N. (2018). Antineoplastic activity of mitomycin C formulated in nanoemulsions-based essential oils on HeLa cervical cancer cells. Chemico-Biological Interactions, 291, 72-80.
    1. Amin, A., Chikan, N. A., Mokhdomi, T. A., Bukhari, S., Koul, A. M., Shah, B. A., Gharemirshamlu, F. R., Wafai, A. H., Qadri, A., & Qadri, R. A. (2016). Irigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in lung cancer cells. Scientific Reports, 6(1), 37151.
    1. Amin, A., Mokhdomi, T. A., Bukhari, S., Wani, S. H., Wafai, A. H., Lone, G. N., Qadri, A., & Qadri, R. A. (2015). Tectorigenin ablates the inflammation-induced epithelial-mesenchymal transition in a co-culture model of human lung carcinoma. Pharmacological Reports, 67(2), 382-387.

Publication types

MeSH terms

LinkOut - more resources